Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro

Cancer Chemotherapy and Pharmacology
Valentina CitiRomano Danesi

Abstract

Everolimus is the hydroxyethyl derivative of sirolimus and a strong inhibitor of mammalian target of rapamycin (mTOR). This drug has immunosuppressive and anticancer activities and the present in vitro study was aimed at identifying the cellular and molecular profiles of breast cancer cells predictive of sensitivity to everolimus. MCF-7, T-47D, ZR-75-1, CAMA-1, HCC-1500 and MCF-10A cells were used and viability was assessed using WST-1 dye. Sensitivity to everolimus was correlated with phosphorylation of AKT (Ser473/Thr308), mTOR (Ser2448), and ERK1/2 (Thr202/Tyr204) and mutational profile of KRAS, NRAS, BRAF, PIK3CA, PTEN, TSC1, TSC2 and FRAP genes. Protein phosphorylation was evaluated by AlphaScreen SureFire, while the mutational status was examined by digital droplet PCR and Sanger sequencing. Everolimus showed a transient growth inhibition in non-tumorigenic cells, while in tumorigenic lines the drug suppressed the proliferation in a concentration-dependent manner but with different potency (IC50) and efficacy (Emax), being ZR-75-1 the most sensitive and T47D the least sensitive. MCF-7, T47D and HCC1500 had activating mutations in PIK3CA gene, while loss-of-activity PTEN mutations were detected in sensitive cell lines, inc...Continue Reading

References

Dec 13, 2005·Nature Reviews. Cancer·Andreas G BaderPeter K Vogt
Jan 27, 2006·The EMBO Journal·Zaira GarcíaAna C Carrera
Feb 2, 2006·British Journal of Cancer·B KarakasB H Park
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Feb 23, 2007·Molecular Cancer Research : MCR·Antoinette HollestelleMieke Schutte
Aug 30, 2008·The Journal of Clinical Investigation·Arkaitz CarracedoPier Paolo Pandolfi
Sep 30, 2008·Breast Cancer Research : BCR·Galatea KallergiVassilis Georgoulias
Jul 2, 2009·Nature Reviews. Drug Discovery·Michael B AtkinsPeter Kirkpatrick
Apr 15, 2011·Molecular Cancer Therapeutics·Ana M Gonzalez-AnguloFunda Meric-Bernstam
May 3, 2011·Trends in Biochemical Sciences·Michelle C MendozaJohn Blenis
Oct 27, 2011·The Journal of Biological Chemistry·Sharon Anavi-GofferRuth A Ross
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Mar 21, 2012·Breast Cancer Research : BCR·Harriet WikmanKlaus Pantel
Mar 19, 2013·The Breast : Official Journal of the European Society of Mastology·Mikhail I Shtivelband
Sep 10, 2013·Nature Chemical Biology·Mohammad Fallahi-SichaniPeter K Sorger
Jan 9, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinath JeselsohnVincent A Miller
Mar 5, 2015·Breast Cancer Research and Treatment·Chiya OshiroShinzaburo Noguchi
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N HortobagyiJosé Baselga
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charlotte FribbensNicholas C Turner
May 23, 2017·Cancer Cell·Yiqun ZhangChad J Creighton

❮ Previous
Next ❯

Citations

Jul 7, 2019·Journal of Hematology & Oncology·Hui HuaYangfu Jiang
Sep 25, 2020·Asia-Pacific Journal of Clinical Oncology·Rana Muhammad UsmanFaiz Anwer
Sep 22, 2018·Molecular Cancer Research : MCR·He ShenJianmin Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.